Predicting breast cancer treatment response using imaging and biopsy data
Part of Cancer, Skin clinical trials.
This study uses your imaging scans and biopsy results to predict how well you might respond to neoadjuvant therapy (chemotherapy or hormonal therapy before surgery). The goal is to help doctors choose the best treatment plan for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have invasive breast cancer confirmed by biopsy.
- You need to be scheduled to receive neoadjuvant therapy (treatment before surgery).
- You must have imaging scans (MRI, ultrasound, or mammogram) and biopsy results from the start.
- You cannot have had radiation to the chest or breast cancer on the same side before.
- Your cancer must not have spread to distant parts of the body (Stage IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
This study is testing an artificial intelligence (AI) tool that reads 3D mammograms (called DBT) to help doctors find and manage breast conditions more accurately and quickly. It could help guide treatment, especially for women getting chemotherapy before surgery.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
This trial uses a special PET/MRI scan combined with artificial intelligence to see if it can predict whether HER2-positive breast cancer will completely disappear after treatment given before surgery. The goal is to learn who might avoid surgery or get a more tailored approach.
This study uses ultrasound and/or MRI scans to see how breast cancer responds early while you start “neoadjuvant” treatment (chemotherapy, with or without radiation before surgery). It may help doctors spot response sooner and better understand which imaging changes match treatment benefit.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.